Outlook Therapeutics Inc.
09/18/2026 | Press release | Distributed by Public on 09/18/2026 14:31
Material Event (Form 8-K)
| Item 8.01 | Other Events. |
On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.
Outlook Therapeutics Inc. published this content on September 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 18, 2026 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]